Scabies is a major public health problem in developing countries, where the bulk of the disease burden falls on children. Vanuatu is no exception; scabies infection is rife. Scabies predisposes patients to bacterial superinfection. In streptococcal skin disease there is also the potential for glomerulonephritis. 1 Malnutrition is a significant problem in areas that have a high incidence of malaria, gastrointestinal and parasitic infection, and scabies and subsequent skin infections are possible further contributing factors.
Topical treatments are the mainstay of scabies treatment world-wide. In developing countries these treatments are often expensive, in short supply and difficult to transport. Compliance is a major problem, especially in areas where water supply is limited. Vanuatu suffers from all of these problems with its standard scabies therapy of topical 10% benzyl benzoate.
Oral ivermectin has repeatedly been shown to be an effective treatment for scabies. [2] [3] [4] It has been used extensively in adults and in children over 5 years old, mostly for the treatment of onchocerciasis. 4 There have been no confirmed reports of serious toxicity after approximately 96 million human treatments. 3 Unfortunately, only limited data exist for its safety in younger children. Ivermectin has the advantage of being cheap and easy to administer as a single, directly observed treatment, thus improving compliance.
The present study compares the efficacy of ivermectin with benzyl benzoate and outlines any adverse reactions in paediatric patients from 6 months to 15 years of age.
METHODS
The present study was an observer-blinded randomized controlled trial undertaken at Vila Central Hospital, Vanuatu, between January 2001 and April 2001. It was performed after local review committee approval and all parents gave their consent prior to enrolment of their children. Children from 6 months to 15 years of age were eligible for enrolment. Exclusion criteria were treatment for scabies within the previous 2 months, major intercurrent illnesses, or a history of meningitis or neurological illness.
Scabies was diagnosed in patients with a consistent history of the disease and typical lesions in the appropriate distribution. A single observer (PB) examined all patients. Data collected at the initial visit included demographic details, the number of lesions, an itch visual analogue score (VAS) and the presence of nocturnal itch. For the purposes of the present study, a scabies lesion was a burrow, an intact papulovesicular lesion or excoriated crusting lesion, and lesions were plotted on a body diagram. Evidence of bacterial superinfection and any administering of antibiotics were noted. Itch VAS was completed by parents for children younger than 7 years and by the children themselves for those 7 years and older.
All patients were weighed and randomized at the hospital pharmacy, based on a computer-generated random number table. Those in the ivermectin arm were given 200 µ g/kg as directly observed treatment. Those in the benzyl benzoate arm were given the mixture and instruction on how to apply it that night at home, as is the standard practice in Vanuatu. Family members were treated with the same medication as the enrolled patients. Children under 6 months old were treated with benzyl benzoate. The importance of washing clothes and bed linen in hot water, if possible, and drying them in the sun were also emphasized.
Observer-blinded follow up was performed 3 weeks after recruitment (PB). Side effects were ascertained, specifically skin reaction to treatment, passage of worms with stool, and abnormal behaviour, such as poor feeding, tremors or listlessness noted by parents or carers.
Data are presented as numerical count and mean ± standard deviation. Fisher's exact test was used for categorical data. Two-tailed Student's t -tests were used to compare the study arms, the number of lesions and the itch VAS. Statistical analyses were undertaken using InStat 2.04 (GraphPad Software, San Diego, CA, USA).
The authors of the present study believed that 15 lesions was a significant clinical difference. Pilot work suggested the likely standard deviation in the number of lesions was 20. Therefore, in order to achieve 90% power, at an alpha level of 0.05, we needed to enrol 38 patients in each group. Allowing for a 30% dropout at follow up, we needed to enrol a minimum of 110 patients.
RESULTS
Eighty (73%) of the initial 110 enrolled patients completed the follow up. The mean age of the patients completing follow up in the ivermectin group ( n = 43) was 5.1 ± 3.9 years, and in the benzyl benzoate group ( n = 37) was 4.7 ± 3.8 years. There was no statistically significant difference in the mean age, the initial number of lesions or the severity of itch in those patients who did not return for follow up compared to those who did.
Both ivermectin and benzyl benzoate produced a significant decrease in the number of lesions, itch VAS and number of patients with nocturnal itch at 3 weeks (Table 1 ). There was no statistically significant difference between the treatments for any of these observations. Ivermectin cured 24 out of 43 patients (56%) (no skin lesions noted at 3 weeks), compared to 19 out of 37 (51%) for benzyl benzoate.
No serious side effects were noted with either treatment. Three children who received ivermectin developed a pustular skin disorder in the days after treatment; one of these children subsequently presented with cellulitis of the arm, and was treated with intravenous cloxacillin in hospital. At the 3-week follow up, he had no evidence of scabies. Parents of six children in the benzyl benzoate arm described burning and stinging after application of the treatment, and a further six children developed a dermatitis reaction. Table 2 summarizes the side effects of the treatments. Benzyl benzoate was significantly more likely to produce a local skin reaction ( P = 0.004, OR 6.4, 95% CI 1.6-25.0) than ivermectin. The passage of worms in stool (based on child or parental observation) was not significantly different between treatment groups ( P = 0.28).
DISCUSSION
Scabies is a major problem in developing countries. Estimations of its incidence in overcrowded areas in India range from 24% to 40% of the population. 5 In Vanuatu, major limiting factors in the effective management of scabies infection are cost, irregular supply of medication and difficulties in washing clothes/sheets. Overcrowding in urban areas and poverty are not easily remediable factors and, unfortunately, provide the setting for continued endemic scabies transmission.
There are multiple topical treatments available for scabies. Permethrin has been shown to be consistently the most effective, with cure rates approaching 100%. 4 It has minimal toxicity and is currently the 'gold standard' in scabies treatment. Unfortunately, its cost prevents routine use in developing countries where the scabies burden is greatest. Benzyl benzoate and lindane are cheaper, but slightly less effective treatments. 3, 6 Lindane has gone out of favour due to the risk of neurotoxicity, particularly in young patients when it is incorrectly used or accidentally ingested. 6, 7 Benzyl benzoate has been shown to cause burning and stinging on broken or excoriated skin, and causes eczematous reactions post-treatment. 6 Ivermectin is cheap and has repeatedly been shown to be an effective and safe treatment for scabies both in randomized trials and in community-based studies. [2] [3] [4] [8] [9] [10] [11] The present study aimed to extend that knowledge to include younger paediatric patients.
More than 96 million doses of ivermectin have been administered in Africa, Latin America and the Middle East in the treatment of onchocerciasis. This includes millions of doses to children aged 5-15 years. 3 In this setting, there have been no reports of serious toxicity. The Mazzotti reaction to the death of filarial parasites is the most frequently reported adverse reaction. Such reactions, which consist of fever, myalgia, headache, arthralgia, anorexia and chills, are seen in up to 24% of patients with microfilaraemia. In contrast, only 0.5% of patients without microfilaraemia report side effects. 8 One report of an increased number of deaths in a nursing home after treatment of a scabies outbreak with multiple drugs, including crotamiton, lindane and ivermectin has not been reproduced in the present study. 12 Several authors have presented similar groups of patients with no increased death rate. 11, 13, 14 The major concern with ivermectin use, particularly in the paediatric age group, is its mechanism of action. Ivermectin blocks transmission across nerve synapses that use glutamate or γ -amino butyric acid (GABA) as their neurotransmitter. This action blocks peripheral motor function in invertebrates, such as Sarcoptes scabiei , resulting in paralysis and death. In humans these synapses exist in the central nervous system. For ivermectin to produce toxicity related to its mechanism of action in humans, it must cross the blood-brain barrier. 15 Idiosyncratic sensitivity in dogs has resulted in deaths, particularly in certain breeds, such as collies. These reactions occur rapidly (within hours of dosing), with a symptom complex of tremors, ataxia, lethargy and eventually coma or death. No long-term effects have been noted in dogs not exhibiting this idiosyncratic reaction. 16 No similar reaction has been noted in humans.
Despite the aforementioned evidence, ivermectin has had limited use in children under 5 years of age. Several small studies have looked at its use in younger patients with scabies and head lice (pediculosis capitis). 3, 17 There are numerous reports of the use of ivermectin in young children for crusted or Norwegian scabies, which are unresponsive to other treatments. [18] [19] [20] There are no reports of serious side effects in any of these studies. Data also exist showing no serious toxicity after accidental ingestion by young children of dog heartworm tablets containing ivermectin. 7 Thus, despite theoretical concerns, there is a limited body of literature that suggests that ivermectin is safe for use in young children.
Our results show ivermectin to be as effective as benzyl benzoate with single-dose treatment. We chose to test singledose therapy, as compliance is a major problem with benzyl benzoate. Multiple dosing with ivermectin is more effective, but compliance then becomes an important limiting factor. 4 In the present study, single doses of both treatments produced a marked reduction in the number of scabies lesions, itch VAS and nocturnal itch. The cure rate was 56% for ivermectin and 51% for benzyl benzoate at 3 weeks.
A previous study by Usha et al . 4 has shown permethrin to be superior to single-dose ivermectin 200 µ g/kg. The treatments were equivalent, however, at the 8-week follow up, where a second dose of ivermectin was given to patients who had had a poor response at 2 weeks (30% of patients in the study by Usha et al. were given a second dose, 70% were cured at 8 weeks with single-dose ivermectin). 4 No serious side effects were noted in our study with ivermectin. A pustular skin disorder in three patients occurred in the days after ivermectin was administered; the incidence of this was not statistically significant. Infective skin disease is common in the study population, and the significance of this is difficult to determine.
Benzyl benzoate had a relatively high incidence of skin side effects, predominantly burning and stinging on application and post-treatment dermatitis. The incidence of these skin side effects with benzyl benzoate treatment was statistically significant.
Thirty patients (27%) failed to return for follow up. Our results for cure, for either treatment, are lower than those previously reported. 2, 4, 8, 9 Thus, we suspect that those patients who did not return for follow up are likely to have been cured. The rates of loss at follow up were not significantly different between the treatment groups. The incentive to return for review is markedly decreased when the problem has resolved. Ivermectin has also been shown to have a delayed time course of clinical effect when compared with permethrin. 4 A second follow-up review may have produced a higher observed cure rate, albeit at the expense of further loss at follow up.
Efficacy, compliance, drug availability and cost were the factors considered in undertaking the present study. There is a high incidence of scabies infection in Vanuatu. Ivermectin has proved to be equally as effective as the current treatment under study conditions. The reality in the normal working environment of the outpatient department is that compliance with a single observed oral treatment is likely to be much higher than topical treatment. Oral treatment offers the additional advantage of rapid treatment of all family members.
The major weakness of the present study is its primary outcome measure; namely the definition of cured scabies in terms of skin lesions rather than live mites. It is likely that the low cure rates for both treatments are related to post-scabies nodules or papular urticarial lesions without mites. However, this would not necessarily have favoured the ivermectin group over the benzyl benzoate group. In addition, the 27% dropout rate is a concern, although dropouts did not differ from those who completed the study.
Ivermectin cost 24VT ($A0.30 per 3.6 mg) for the average patient in the present study, compared with 50VT ($A0.63 per 100 mL) for benzyl benzoate. In addition, the cheaper transportation and storage costs of tablets make ivermectin significantly more attractive than benzyl benzoate.
CONCLUSIONS
Ivermectin is equally as effective as benzyl benzoate for the treatment of paediatric scabies. It is cheap and more easily transported than benzyl benzoate. Ivermectin has an extensive safety history in patients older than 5 years, and, thus far, there are no reported cases of serious toxicity in younger children. Given ivermectin's action against other parasites, its ease of use and its suitability as a directly observed treatment, we believe it to be better than benzyl benzoate for the treatment of paediatric scabies in developing countries.
